Wockhardt may suffer an annual revenue fall of up to $250 million and its American operations may grind to a halt after the US’s drug regulator banned the sale of medicines produced from the firm’s Chikalthana plant in the world’s biggest pharma market. The United States Food and Drug Authority (USFDA) did not cite the reasons for the ban but had warned the company over poor hygiene and absence of good manufacturing practices when it imposed a similar ban on Wockhardt’s Waluj plant in July.

Source : http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/wockhardt-revenues-may-dip-up-to-250-m-on-usfda-ban/articleshow/26491666.cms